Quarry Thera is a biotech company advancing next-generation proximity-induced therapeutics using molecular glues. Molecular glues represent a powerful new drug modality, leveraging proprietary DNA-encoded libraries, structure-based design, and advanced medicinal chemistry to overcome challenges like limited efficacy, poor permeability, and the difficulty of targeting undruggable proteins.
Sector: Life Sciences
iRiva Medical
iRiva Medical is developing next-generation neuromodulation technology aimed at treating chronic diseases. The company focuses on addressing unmet clinical needs for large patient populations through innovative implantable medical devices.
Arnatar Therapeutics
Arnatar is reimagining RNA medicines to precisely silence disease drivers or restore what’s missing. Through their dual-modality DARGER™ platform, they develop best-in-class siRNA and first-in-class upregulating ASOs for cardiometabolic, liver, CNS, and kidney diseases.
Apreo Health
Apreo Health is redefining interventional pulmonology with a non-destructive, tissue-sparing solution for severe emphysema—one of the most under-treated and misunderstood diseases in medicine. Apreo is led by a team with deep expertise in both pulmonary medicine and medical device innovation. The company is advancing a therapy purpose-built to expand access, simplify delivery, and transform the treatment pathway for patients with severe emphysema.
Namandjé N. Bumpus, PhD
Dr. Namandjé N. Bumpus joined F-Prime in 2025, where she serves as a strategic advisor on regulatory science, regulatory affairs, and policy, bringing deep expertise from her previous roles as FDA Principal Deputy Commissioner and Chief Scientist. Before the FDA, Dr. Bumpus was the E.K. Marshall and Thomas H. Maren Professor and director of the Department of Pharmacology and Molecular Sciences at the Johns Hopkins University School of Medicine, where her research advanced understanding of drug metabolism, mechanisms of drug-induced toxicity, pharmacogenetics, bioanalytical chemistry, infectious disease pharmacology, and single cell biology. She completed her postdoctoral fellowship at The Scripps Research Institute and holds a PhD in pharmacology from the University of Michigan and a bachelor’s degree in biology from Occidental College.
Dr. Bumpus is a past-president of the American Society for Pharmacology and Experimental Therapeutics, a fellow of the American Association for the Advancement of Science, and a member of the National Academy of Medicine.
Catherine Stehman-Breen
Catherine Stehman-Breen is a Venture Partner at F-Prime based in the Cambridge office, focusing on new company creation. She has more than 30 years of medical and biopharmaceutical experience. Prior to joining F-Prime, Catherine was CEO of Chroma Medicine, a company developing a novel epigenetic editing therapeutics platform where she built the company from inception. Previously, she was Chief Research and Development Officer at Obsidian Therapeutics, a cell therapy company developing engineered tumor infiltrating lymphocyte therapies for patients with solid tumors. As Entrepreneur in Residence at Atlas Venture, she worked closely with start-ups across a range of technologies and previously served as Chief Medical Officer at Sarepta Therapeutics. In addition, Catherine held various leadership roles at Regeneron and Amgen.
Catherine earned her MD from the University of Chicago. She completed her residency and nephrology fellowship training at the University of Washington, where she also received an MS in epidemiology. Catherine served as a faculty member in the division of nephrology and remains an affiliate associate professor in the University of Washington School of Public Health, with more than 90 publications in medical journals.
Laurus Bio
Laurus Bio is an integrated research-driven biomanufacturing organization specializing in precision fermentation and recombinant technology. They develop sustainable, animal-free proteins and growth factors, replacing animal-derived products in various industries. Laurus Bio also offers CDMO services for microbial fermentation-based manufacturing and product development.
Rugen Therapeutics
Countable Labs
Countable Labs is redefining PCR with single-molecule precision and category-defining sensitivity, overcoming the limitations of legacy technologies. Countable PCR delivers 10 times the sensitivity and precision of digital PCR in a single reaction. Plus, it speeds up assay development with simplified multiplexing. These breakthroughs unlock high-sensitivity applications that were previously impractical due to cost and complexity.
Insmed
Insmed Incorporated is a biopharmaceutical firm focused on developing therapies for serious and rare diseases, including respiratory and inflammatory conditions. Its flagship product, Arikayce, targets treatment-refractory Mycobacterium avium complex lung disease.